Development of robust iPSC-based α-Synuclein, Tau and TDP-43 aggregation models for drug discovery
A human scalable platform for high-throughput screening of drug candidates targeting pathological aggregation of TAU, αSynuclein and TDP-43
Building manufacturing processes for reproducible, multi-yeariPSC-based drug screening
Advancing cardiovascular drug discovery with iPSC-Derived 3D cardiac microtissues in High-Throughput Screening
Development of a robust and scalable iPSC platform for predictions of efficacy and in vivo toxicity of RNA therapeutics early in the drug discovery pipeline
Building manufacturing processes for reproducible, multi-yeariPSC-based drug screening
Subscribe to our newsletter
Stay up to date on iPSC innovations, events and news.
